In this podcast, PRI senior fellow Wayne Winegarden discusses why ICER’s reports contain biased, inaccurate assumptions.
Watch Professor Salvare take Pete Paystoomuch in a time machine to learn how drugs become cheaper after higher initial costs that incentivize innovation.
On the first step toward escaping the pricing maze, Professor Salvare takes Pete Paystoomuch down the path of drug innovation, showing him why drug prices are initially more expensive – to cover all of the costs that go into developing a new medicine.
How the direction policymakers take on drug pricing policy could impact the affordability and availability of current medicines, and innovation that could lead to future, life-saving cures.
To ensure the ongoing affordability of generic medications for Americans, BCBS is committing $55 million to establish a partnership with Civica Rx to reduce costs of generics for consumers.